Ironwood Pharmaceuticals to Present at the Jefferies Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies Healthcare
Conference on Thursday, June 8, 2017 at 4:00 p.m. Eastern Time at the Grand Hyatt in New York City. The presentation will be
followed by a question and answer session at 4:30 p.m. Eastern Time.
A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes
prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be
available on Ironwood’s website for 14 days following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a
difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two
innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome
with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine
oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. We are also advancing a pipeline of
internally and externally generated innovative product candidates in areas of significant unmet need, including uncontrolled
gastroesophageal reflux disease and vascular and fibrotic diseases. Ironwood was founded in 1998 and is headquartered in Cambridge,
Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both
these locations.
Ironwood Pharmaceuticals, Inc.
Media Relations
Trista Morrison, 617-374-5095
Director, Corporate Communications
tmorrison@ironwoodpharma.com
or
Investor Relations
Meredith Kaya, 617-374-5082
Senior Director, Investor Relations
mkaya@ironwoodpharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170601005132/en/